Stifel Nicolaus lowered shares of Innocoll Holdings PLC (NASDAQ:INNL) from a buy rating to a hold rating in a research report released on Friday morning. The firm currently has $2.00 price objective on the specialty pharmaceutical company’s stock, down from their previous price objective of $9.00.

A number of other equities research analysts also recently issued reports on INNL. Zacks Investment Research downgraded Innocoll Holdings PLC from a buy rating to a hold rating in a research report on Wednesday, November 30th. Janney Montgomery Scott downgraded Innocoll Holdings PLC from a buy rating to a neutral rating and set a $2.00 price target for the company. in a research report on Friday, December 30th. JMP Securities downgraded Innocoll Holdings PLC from an outperform rating to a market perform rating in a research report on Friday, December 30th. Finally, FBR & Co downgraded Innocoll Holdings PLC from an outperform rating to a market perform rating and boosted their price target for the company from $2.00 to $10.00 in a research report on Friday, December 30th. Five equities research analysts have rated the stock with a hold rating, The stock currently has a consensus rating of Hold and a consensus target price of $3.69.

Innocoll Holdings PLC (NASDAQ:INNL) traded down 9.1840% on Friday, hitting $1.1352. The stock had a trading volume of 541,032 shares. The firm’s market cap is $33.72 million. Innocoll Holdings PLC has a 12-month low of $0.53 and a 12-month high of $12.94. The company’s 50 day moving average is $0.78 and its 200 day moving average is $2.97.

Your IP Address:

A hedge fund recently raised its stake in Innocoll Holdings PLC stock. Prudential PLC boosted its position in shares of Innocoll Holdings PLC (NASDAQ:INNL) by 19.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,079,172 shares of the specialty pharmaceutical company’s stock after buying an additional 173,833 shares during the period. Prudential PLC owned about 3.63% of Innocoll Holdings PLC worth $745,000 at the end of the most recent reporting period. 42.88% of the stock is owned by hedge funds and other institutional investors.

About Innocoll Holdings PLC

Innocoll Holdings Public Limited Company is a commercial-stage specialty pharmaceutical and medical device company with late-stage development programs. The Company operates through the segment of manufacture and sale of collagen-based pharmaceutical products. It utilizes collagen-based technology platform to develop its biodegradable and bioresorbable products and product candidates, which can be broken down by the body without the need for surgical removal or applied topically.

5 Day Chart for NASDAQ:INNL

Receive News & Ratings for Innocoll Holdings PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innocoll Holdings PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.